Egenesis Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 98

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $125M

  • Investors
  • 28

Egenesis General Information

Description

Developer of a gene editing and genome engineering platform intended to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases. The company's platform offers gene editing technics for the development of human-compatible organ tissue cells, and also leads programs in kidney and islet cell transplantation, enabling patients to recover and lead a healthy life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Corporate Office
  • 101 Cambridgepark Drive
  • Suite 200
  • Cambridge, MA 02140
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Egenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 01-Mar-2021 $125M 00000 00000 Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 01-Nov-2019 00000 00000 00000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 13-Mar-2017 $38M $38M 000.00 Completed Pre-Clinical Trials
To view Egenesis’s complete valuation and funding history, request access »

Egenesis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 21,934,976 $0.000020 $0.14 $1.8 $1.8 1x $1.8 12.23%
To view Egenesis’s complete cap table history, request access »

Egenesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a gene editing and genome engineering platform intended to transform solid organ and therapeutic cell trans
Biotechnology
Cambridge, MA
98 As of 2023
00000
0000 0000-00-00
00000000000 00000

000000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000000000000
Cambridge, MA
000 As of 0000
00000
00000000 00000

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc
0000000000000
Mountain View, CA
00 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Egenesis Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Cellecta Private Debt Financed Mountain View, CA 00 000000000 -
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
Immusoft Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
Homology Medicines Formerly VC-backed Bedford, MA 00 00000 000000&0 00000
You’re viewing 5 of 40 competitors. Get the full list »

Egenesis Patents

Egenesis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021380845-A1 Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020 00000000000
CA-3198027-A1 Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020 00000000000
GB-202308468-D0 Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020 00000000000
EP-4244352-A1 Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020 00000000000
GB-2618225-A Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance Pending 13-Nov-2020 A01K67/0278
To view Egenesis’s complete patent history, request access »

Egenesis Executive Team (19)

Name Title Board Seat Contact Info
Luhan Yang Ph.D Co-Founder, President, Co-Chief Scientific Officer & Board Member
Knut Niss Ph.D Chief Technology Officer
Elizabeth Roberts Chief People Officer
Luis Queiroz Strategic Advisor
Lauren Tahmoush Controller
You’re viewing 5 of 19 executive team members. Get the full list »

Egenesis Board Members (15)

Name Representing Role Since
Albert Wiegman Fresenius Medical Care Ventures Board Member 000 0000
Bradford Smith Egenesis Board Member 000 0000
Daniel Lynch Self Executive Chairman 000 0000
Isaac Ciechanover MD Polaris Partners Board Member 000 0000
Julie Sunderland Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Egenesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Egenesis Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Altium Capital Investment Bank Minority 000 0000 000000 0
Altium Capital Management Growth/Expansion Minority 000 0000 000000 0
Catalio Capital Management Venture Capital Minority 000 0000 000000 0
E Squared Capital Management Hedge Fund Minority 000 0000 000000 0
Farallon Capital Management Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 28 investors. Get the full list »

Egenesis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ICBiotec 20-May-2020 0000000000 Drug Discovery 0000 0000
To view Egenesis’s complete acquisitions history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »